logo
Plus   Neg
Share
Email

Bilfinger Shareholders Approve Settlement With Former Executive Board Members

German engineering group Bilfinger (BFLBY.PK) said that a large majority of its shareholders voted in favor of the settlement with former Executive Board members at virtual Annual General Meeting.

The company noted that the settlement has ended the company's assertion of claims for damages against twelve former Executive Board members and has a total volume of 18.2 million euros. In addition to the waiver of salary claims, Bilfinger will receive an amount of 16.75 million euros from the D&O insurers in the near future.

A further resolution of the Annual General Meeting related to the election of Bettina Volkens and Robert Schuchna as shareholder representatives to the Supervisory Board of Bilfinger SE.

Volkens and Schuchna succeed Nicoletta Giadrossi and Jens Tischendorf, who stepped down from their positions at the Annual General Meeting.

In light of the uncertain environment, the Executive Board and Supervisory Board proposed to the Annual General Meeting a dividend of 0.12 euros per share - the minimum amount as required by law. The Annual General Meeting voted in favor of this proposal with a large majority.

The company continues to anticipate the gradual recovery of its business in the second half of the year and remain committed to its financial targets for 2024.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT